YAP1, neointima formation, and blood pressure regulation
YAP1, neointima formation, and blood pressure regulation
批准号:
10040710
负责人:
Islam Osman
金额:
$12.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-05 至 2022-07-31
关键词:
AcetatesActinsAngioplastyAngiotensin IIAnimal ModelAntihypertensive AgentsArterial InjuryAtherosclerosisAttenuatedBiological AssayBlood PressureBlood VesselsCardiovascular DiseasesCause of DeathCell Culture TechniquesCollaborationsDataDeoxycorticosteroneDiseaseEtiologyExhibitsGenesGenetic TranscriptionGoalsHypertensionImpairmentIn VitroInfusion proceduresInjuryKnockout MiceLuciferasesMeasuresMediatingMuscle ContractionPRKCA genePharmacologyPhasePhenotypePlatelet-Derived Growth FactorPlatelet-Derived Growth Factor beta ReceptorPreventionProteinsRegulatory PathwayReporterResearchResistanceRoleSignal TransductionSingle Nucleotide PolymorphismSmooth MuscleSmooth Muscle MyocytesSodium ChlorideStructureTelemetryTestingTrainingTransgenic AnimalsUnited StatesVascular DiseasesVascular Smooth MuscleVascular remodelingVascular resistanceVasoconstrictor Agentsbasebeta Actinblood pressure reductionblood pressure regulationcareergenome wide association studygenomic locusin vivoindexinginhibitor/antagonistinsightloss of functionmouse modelneointima formationnovelnovel therapeutic interventionnovel therapeuticspolymerizationreceptorresponserestenosistranscription factortranslational approachvascular smooth muscle cell proliferation
中文摘要
项目摘要
血管平滑肌细胞(VSMC)的表型调节是多血管壁病变病因学的核心,
疾病 在血管成形术后再狭窄和动脉粥样硬化中,VSMC获得增殖/迁移能力,
表型导致新生内膜形成。 相比之下,高血压主要是由血管性高血压引起的。
这是由于过度的VSMC收缩和血管重塑造成的。钥匙的识别
调节VSMC增殖和收缩的参与者对于进一步了解VSMC的基本功能至关重要。
VSMC-CD 4驱动的血管壁疾病的机制,以及开发新的治疗方法。我们
先前已经证明转录辅因子YAP 1促进VSMC的增殖,
增殖 然而,YAP 1在体内新生内膜形成中的作用和潜在机制仍不清楚。
此外,最近的全基因组关联研究(GWAS)已经确定了一个功能缺失的单克隆抗体,
YAP 1基因位点的一个核苷酸多态性(SNP),意外地与低血
这表明YAP 1在血压调节中的新作用。本提案的总体目标是
以确定YAP 1在调节VSMC增殖和收缩/高血压中的作用。 小说
该提议的初步数据包括:1)动脉损伤后YAP 1表达上调,
与VSMC增殖在体内,2)YAP 1,与TEA结构域转录因子1(TEAD 1),
血小板源性生长因子受体β(PDGFRb β),一种新的调控VSMC的YAP 1靶基因
表型,3)SM-β特异性Yap 1敲除小鼠表现出肿胀表型和对
在离体血管中的血管收缩剂,和4)在VSMC中沉默YAP 1抑制蛋白激酶C α(PRKCa β)
信号传导和受损的肌动蛋白聚合,这是VSMC收缩的关键。 三个具体目标是
提出测试中心假设,即YAP 1诱导VSMC增殖和收缩,以驱动新生内膜
形成和高血压,分别。 K99 Aim 1. 检验YAP 1诱导PDGFRb表达的假设,
促进VSMC增殖,增强损伤诱导的新生内膜形成。 第二章. 测试
假设YAP 1激活PRKCa β信号并促进肌动蛋白聚合以增强VSMC
收缩。3.验证VSMC-β表达YAP 1是实验性高血压的基础的假设。
这些研究的完成将为VSMC表型调控机制提供新的见解。
并将确定抑制YAP 1是否是一种有吸引力的新治疗方法
改善闭塞性血管疾病和高血压的策略。 更多的概念和
在K99阶段,高血压相关研究的实验培训将有助于申请人追求
在R 00阶段,将此提案转换为R 01应用程序。
英文摘要
PROJECT SUMMARY
Vascular smooth muscle cell (VSMC) phenotypic modulation is central to the etiologies of multiple vascular wall
diseases. In post-angioplasty restenosis and atherosclerosis, VSMCs acquire a proliferative/migratory
phenotype leading to neointima formation. In contrast, hypertension is largely caused by increased vascular
resistance that is attributed to exaggerated VSMC contraction and vascular remodeling. Identification of the key
players that regulate VSMC proliferation and contraction is critical for further understanding of the underlying
mechanisms of VSMC-driven vascular wall diseases and also for developing novel therapeutic approaches. We
have previously demonstrated that the transcription co-factor yes-associated protein 1 (YAP1) promotes VSMC
proliferation. Yet, the role and underlying mechanisms of YAP1 in neointima formation in vivo remain unclear.
Furthermore, recent genome-wide association studies (GWAS) have identified a loss-of-function single
nucleotide polymorphism (SNP) in YAP1 gene locus that was unexpectedly associated with lower blood
pressure, suggesting a novel role of YAP1 in blood pressure regulation. The overarching goal of this proposal is
to determine the role of YAP1 in regulating both VSMC proliferation and contraction/hypertension. Novel
preliminary data in this proposal include 1) YAP1 expression is upregulated after arterial injury and correlates
with VSMC proliferation in vivo, 2) YAP1, in association with TEA domain transcription factor 1 (TEAD1), induces
platelet-derived growth factor receptor beta (PDGFRb), a putative novel YAP1 target gene that regulates VSMC
phenotype, 3) SM-specific Yap1 knockout mice exhibit a hypotensive phenotype and an attenuated response to
vasoconstrictors in isolated vessels, and 4) silencing YAP1 in VSMCs inhibited protein kinase C alpha (PRKCa)
signaling and impaired actin polymerization, which are key for VSMC contraction. Three specific aims are
proposed to test the central hypothesis that YAP1 induces VSMC proliferation and contraction to drive neointima
formation and hypertension, respectively. K99 Aim 1. Test the hypothesis that YAP1 induces PDGFRb to
promote VSMC proliferation and enhance injury-induced neointima formation in vivo. R00 Aim 2. Test the
hypothesis that YAP1 activates PRKCa signaling and promotes actin polymerization to enhance VSMC
contraction. R00 Aim 3. Test the hypothesis that VSMC-expressed YAP1 underlies experimental hypertension.
Completion of the proposed studies will provide novel insights into the mechanisms regulating VSMC phenotypic
modulation and blood pressure regulation and will determine if inhibiting YAP1 is an attractive novel therapeutic
strategy for ameliorating both occlusive vascular diseases and hypertension. Additional conceptual and
experimental training in hypertension-related research during the K99 phase will help the applicant pursue an
independent career and transform this proposal into an R01 application during the R00 phase.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
YAP1, neointima formation, and blood pressure regulation
-
批准号:10731404
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2022
-
负责人:Islam Osman
-
依托单位:
YAP1, neointima formation, and blood pressure regulation
-
批准号:10229472
-
项目类别:
-
资助金额:$12.29万
-
财政年份:2020
-
负责人:Islam Osman
-
依托单位:
海外基金